A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis

Trial Profile

A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 May 2017

At a glance

  • Drugs Tobramycin (Primary)
  • Indications Pseudomonal infections
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 05 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 10 Feb 2014 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.
    • 27 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top